Modeling Potential Responses to Smallpox as a Bioterrorist Weapon

Martin I. Meltzer,* Inger Damon,* James W. LeDuc,* and J. Donald Millar†

*Centers for Disease Control and Prevention, Atlanta, Georgia, USA; and †Don Millar & Associates, Inc., Atlanta, Georgia, USA

We constructed a mathematical model to describe the spread of smallpox after a deliberate release of the virus. Assuming 100 persons initially infected and 3 persons infected per infectious person, quarantine alone could stop disease transmission but would require a minimum daily removal rate of 50% of those with overt symptoms. Vaccination would stop the outbreak within 365 days after release only if disease transmission were reduced to >0.85 persons infected per infectious person. A combined vaccination and quarantine campaign could stop an outbreak if a daily quarantine rate of 25% were achieved and vaccination reduced smallpox transmission by >33%. In such a scenario, approximately 4,200 cases would occur and 365 days would be needed to stop the outbreak. Historical data indicate that a median of 2,155 smallpox vaccine doses per case were given to stop outbreaks, implying that a stockpile of 40 million doses should be adequate.

Recent papers have speculated about the use of smallpox as a biological weapon (1-5). If we assume such a risk, there is concern about the need for preparations to limit and prevent the spread of smallpox after a deliberate release of the virus. Studies of smallpox control and eradication efforts (6-8) identified two available types of interventions: vaccination of those at risk from infection, quarantine, or both. Some studies have provided estimates of the potential numbers that could be infected (1,3,5) and the number of vaccine doses that should be stockpiled (5); however, they did not provide details of how these estimates were calculated. Further, none of these articles examined how quarantine of infected persons may help halt transmission of smallpox.

Crucial questions that remained unanswered include—How can we calculate the number of doses of smallpox vaccine to be stockpiled? Can quarantine contribute to control efforts? How effective does quarantine have to be to reduce transmission? We present a mathematical model that helps answer these and other questions.

Methods

We constructed a mathematical model to meet the following objectives: 1) describe the spread of smallpox through a susceptible population, calculating daily (new-onset) and cumulative cases; 2) readily accommodate changes in input values, such as the number of persons infected per infectious person (i.e., rate of transmission) and the number of persons initially infected; 3) examine the impact of quarantine and vaccination, alone and in combination, on the spread of smallpox; and 4) estimate the number of doses of smallpox vaccine that should be stockpiled as part of readiness plans.

Despite numerous reports of mathematical models of infectious diseases (9-14), few such models describe the spread of smallpox. Frauenthal (15) addressed the question of optimal level of smallpox vaccination. We constructed a Markov chain model (16) to describe the spread of smallpox through a susceptible population (objective 1), using a computer-based spreadsheet program (Excel97, Microsoft, Redmond, WA). The model describes four disease stages: incubating, prodromal, overtly symptomatic, and no longer infectious (Figure 1). The term “prodromal” indicates the preeruptive stage.1 “Overtly symptomatic” refers to the period of disease when a rash or similar symptoms can be readily noted by even an untrained observer.2 For each day after the release, the model calculates both the number of new cases and the cumulative total.

In the model, an infected person can only progress, from incubating to prodromal to overtly symptomatic, and cannot revert. The duration in days of a given disease stage is controlled by a probability function (Figure 2).

Probable Durations of Each Disease Stage

When smallpox was endemic in human populations, the incubation period was often difficult to measure because many patients were exposed over several days (7,8). Fenner et al. (7) reviewed and summarized three reports in which the incubation period was calculated for 255 cases of variola major smallpox (the “classic” form). Just over 70% of these cases incubated 9 to 13 days, with an average of 11.5 days (range 7 to 19 days; median approximately 11 days; 5th

---

1Others have suggested that the terms “preeruptive” or “initial” are more descriptively accurate of this stage (6). However, because “prodromal” is used in many standard textbooks (7,8,17), we will use this term.

2Prodromal rashes have been recorded, but they were considered to be uncommon occurrences, “... not more than 1 in 10.” (17).
Using data from 115 cases in Europe (19), we constructed a reverse cumulative probability function to describe the probability of a person on a given day remaining in the state of incubation for the next day (Figure 2). The calculated mean was 11.7 incubating days (median approximately 11 days; 5th percentile 8 days; and 95th percentile 17 days). The function used can be altered to reflect other data sets or hypothesized functions. Further, the model can accept different transition probability functions for each day in the model.

The duration of the prodromal stage is variable and depends in part on the ability of the physician or patient to detect the first lesion (6). The onset of rash (the overtly symptomatic stage) typically occurs 48 to 72 hours after onset of fever, although some types of smallpox may have a prolonged prodromal stage of 4 to 6 days (6). Fenner et al. reviewed several data sources and used temperature data to report that the prodromal stage lasts an average of 3 days (7). Beyond these descriptions of the average or typical course of disease, no data are readily available documenting the probabilities associated with a longer prodromal stage (e.g., frequency data linking number of patients to number of days in the prodromal stage). Thus, we assumed a linear decline in the daily probability of remaining in the prodromal stage (Figure 2). The probabilities decline from 0.95 at the end of day 1 (i.e., a 95% chance that the patient will be in prodromal stage for another day) to 0.00 at the end of day 3 (i.e., absolute certainty that the prodromal stage will not last beyond day 3).

The average total time of illness (i.e., having some symptoms) is given in Fenner et al. (7) as 21 days, with scabbing on day 19. Allowing up to 3 days for the prodromal period (Figure 2) leaves an average of 16 days in the overtly symptomatic period in which a patient can infect others. Although scabs may contain infectious amounts of smallpox virus after the patient has fully recovered, we assumed that after scabbing, neither the patient nor the scabs will pose a substantial source of infection. The exact duration of illness is somewhat moot, as the likelihood of transmission declines after the first few days of overt symptoms. Thus, after some period, a person who is overtly symptomatic has a low probability of infecting a susceptible person. We assumed a probability of 1.00 (i.e., absolute certainty) of remaining the next day in the overtly symptomatic stage for the first 10 days in the stage. Including the prodromal stage, this corresponds to 12-15 days of illness (Figure 2). After 10 days, a patient’s daily probability of remaining in the stage decreases linearly, so that 15 days after onset of symptoms the probability of remaining the next day in this stage is 0.00 (Figure 2). That is, after a maximum of 16 days in the overtly symptomatic stage, all patients will have progressed to the “no longer infectious” stage. Patients who have reached the fourth and final stage (no longer infectious) effectively drop out of the model. These probability functions can readily be changed (objective 2).

Likelihood of Smallpox Transmission

Also described by a probability function is the likelihood of smallpox transmission during the infectious period. For a variety of reasons, the probability of transmission is likely to change during the period when an infected person is infectious. For example, persons with a high fever during the first...
2 days of the prodromal stage (Figure 2) may voluntarily confine themselves to quarters, possibly limiting their opportunities to infect others. Limited data are available regarding changes in the probability of when an infection is transmitted, but Mack (19) and Rao (6) provide a time series of data involving 23 and 60 patients, respectively. Both data sets suggest that transmission is less likely during the prodromal stage (the first 3 days when a person is symptomatic) and that the probability of transmission is greatest between days 3 and 6 after a patient becomes infectious (Figure 3). This period is equivalent to the first to third days of onset of rash (overt symptoms). Both data sets (6,19) indicate that 70% to 80% of transmission is likely to occur in the first 9 days of the symptomatic period, and 90% of all transmission will have occurred in 10 to 13 days (Figure 3). In other words, by day 6 of overt symptoms (rash), approximately 75% of transmissions will have occurred, with 90% occurring within 7 to 10 days. For the model, we used the data from Mack (19) to describe the probabilities of when transmission will occur, from infectious to newly infected (Figure 3). Other data sets and probability functions can readily be substituted.

Existing Immunity and Community Size

For simplicity, we assumed an unlimited supply of susceptible persons, so that disease transmission will not be halted because of lack of susceptible persons. Although this scenario is unrealistic for modeling the natural spread of an infectious disease, it may be realistic for considering the initial spread of an infectious disease after deliberate infection of a small number of persons in a population with a relatively large proportion who are susceptible.

Another variable that can alter the transmission rate and persistence of disease is size of community. Smith (22) summarized data evaluating the link between community size and spread of some infectious diseases and found that the larger the community, the higher the rate of transmission. This observation was found to be true for measles, scarlet fever, diphtheria, and whooping cough (pertussis), but smallpox was not analyzed (22-24). Arita et al. (25) found a correlation between increasing density of smallpox-susceptible persons and the persistence of smallpox within a population but did not estimate the relationship between susceptible population density and transmission rate. Our model allows for the impact of different densities of susceptible persons by adjusting the average transmission rate.

Numbers Initially Infected and Rate of Transmission

Based on Henderson’s comment that an outbreak of smallpox “...in which as few as 100 people were infected would quickly tax the resources of any community” (1), we initially assumed that 100 persons would be effectively exposed, infected, and become infectious. We set the average transmission rate at 3, which is notably higher than most historical averages. (A mathematical review of the transmission of smallpox appears in Appendix I, available at URL: http://www.cdc.gov/ncidod/eid/vol7no6/meltzer_appendix1.htm). We define the term “transmission rate” as the number of persons infected per infectious person, rather than the number of persons infected during a standardized unit of time. During sensitivity analyses, we altered both the number of persons initially infected and the rate of transmission.

Modeling the Effects of Potential Interventions

We examined the effect of quarantine and vaccination, alone and in combination (objective 3). Quarantine was modeled by removing daily a fixed proportion of a cohort of infectious persons, starting on the day that they become overtly symptomatic. For example, we assumed that 50% of all persons with rashes on day 1 of the overtly symptomatic period would be successfully quarantined and not infect anyone else. Fifty percent of those who missed quarantine on day 1 of rash would be quarantined on day 2. This proportionate reduction would continue for the duration of time that persons are likely to infect others. The model also calculated the number of infectious persons needed to be quarantined under a given scenario.

For a vaccination-only strategy to stop transmission, sufficient susceptible persons must be effectively vaccinated so that the number of persons infected per infectious person is less than 1. We thus evaluated how long it would take to stop an outbreak if the level of transmission were reduced to 0.99 persons infected per infectious person. We also calcu-

Figure 3. Daily and cumulative probabilities determining when an infectious person infects another person with smallpox (6,19). Day 1 of the infectious period is the first day of the prodromal stage. That is, we have interpreted the source data to reflect the assumption that no spread of infection can occur while an infected person is in the incubating stage.

The United States stopped routine vaccination of the civilian population in 1972 (5). In July 1998 in the United States, there were approximately 109.9 million persons <30 years of age, representing 41% of the total resident population (20). Most of these people have not been vaccinated against smallpox. In addition, the immunologic status of those who were vaccinated >30 years ago must be considered. Historical data indicate that vaccination 20 to 30 years ago may not protect against infection but will often protect against death (6,21). No reports, however, define the probability of such persons transmitting the disease to susceptible persons. Faced with such uncertainty, we chose the simplest approach of assuming an unlimited supply of susceptible persons.

At a 50% daily removal rate, a cohort of all those beginning the first day of overt symptoms is entirely removed in 7 days (8 to 10 days postincubation), with 90% removed in 4 days after they enter the overtly symptomatic period. At a 25% daily removal rate, a cohort is entirely removed 17 days after entering the overtly symptomatic period (18 to 20 days postincubation), with 90% removed in 9 days after entering the overtly symptomatic period. The calculated numbers of those quarantined relate only to those who are infectious (i.e., overtly symptomatic). The model does not take into account those who might also be quarantined along with the infectious persons, such as unvaccinated household contacts and other exposed persons.
lated the smallest vaccine-induced reduction in transmission required to stop the outbreak within 365 days postrelease. This calculation was done by an iterative process in which the rate of transmission was reduced until the number of new cases per day reached approximately zero 365 days after release. To estimate the impact of vaccination, we assumed that a vaccination campaign would immediately reduce the risk of transmission, and we did not model the time required from vaccination to effective vaccine-derived immunity. This assumption may overstate the impact of vaccination, particularly in terms of how quickly a vaccination campaign could stop an outbreak.

Lane and Millar estimated that continuing routine childhood immunization against smallpox in the United States from 1969 to 2000 would cause 210 vaccine-related deaths (26). That calculation was made before the population included substantial numbers of immunocompromised persons (e.g., HIV- or cancer therapy-induced immune suppression). Because of the potential for adverse vaccine-related side effects, it may be prudent to attempt to limit the number of persons vaccinated. We therefore calculated the impact of limiting the numbers vaccinated so that transmission would be reduced by just 25%, from 3 to 2.25 persons infected per infectious person, combined with a daily quarantine rate of 25%. We also calculated, by an iterative process, the smallest vaccine-induced reduction in transmission required to stop the outbreak within 365 days postrelease when combined with a daily quarantine rate of 25%.

Start of Interventions

We considered the effect of starting large-scale, coordinated interventions on days 25, 30, and 45 postrelease, assuming release on day 1. Twenty-five days assumes 15 days for the first signs of overt symptoms (Figure 2), 2 days for initial clinical diagnosis, 1 day for specimen transport, 3 days for laboratory confirmation, and 4 days to mobilize and begin appropriate large-scale interventions. Although interventions may begin on a small scale earlier than day 25, in the model the term “start of interventions” refers to the date when a full-scale and comprehensive intervention begins (i.e., the model does not allow for a gradual increase of intensity in interventions). If we assume that an average of 15 days will be needed for those infected to become infectious (Figure 2), 30 days represents the time when the first generation of cases (those infected by the index cases) will begin to show overt symptoms. Forty-five days represents the time needed for the second generation of cases (those infected by the first generation) to show overt symptoms.

Numbers Vaccinated per Case: Stockpile Issues

To determine the number of persons that must be vaccinated, we searched for reports of successfully contained smallpox outbreaks in which both the number of cases and the number of doses of vaccine administered were recorded. These data allowed us to assemble a data set of doses used per case, which was then fitted to probability distributions by using specialized software (Bestfit, Palisade Corp, Newfield, NY). The probability distribution that gave the “best fit,” judged by standard tests (chi square, Kolmogorov-Smirnov, Anderson-Darling), provided the mean and median number of doses historically used per case of smallpox, as well as confidence intervals (e.g., 95th, 90th, and 10th percentiles). We then estimated the total number of vaccine doses that should be stockpiled by multiplying the estimated doses per case by the number of cases estimated by the Markov chain model (objective 4).

Other Potential Interventions

We did not consider other potential preparations, such as routine mass immunizations against smallpox. Reasons for this exclusion include uncertainties about cost, vaccine safety, duration of vaccine efficacy, and the probability of such an event.

Sensitivity Analyses

We examined the effect on the number of daily and total cases when the number initially infected was changed from 100 to 1,000 and the transmission rate was decreased to 2 or increased to 5 persons infected per infectious person. We also used the model to determine the minimum level of interventions needed to ensure that transmission stopped by given target dates. We chose 75, 150, and 225 days postrelease as the examples of target dates, representing 5, 10, and 15 generations of smallpox, respectively. The minimum levels of intervention needed to achieve these targets were determined by an iterative process, altering the level of the intervention(s) until the number of new cases per day reached zero on each target date.

Results

Effect of Transmission Rate and Numbers Initially Infected

We calculated the hypothetical effect of allowing smallpox to spread without intervention, assuming an unlimited supply of smallpox-susceptible persons. The data demonstrate that the most important mathematical variable is the assumed rate of transmission. For a given number of persons initially infected, doubling the number infected per infectious person causes a massive increase (greater than 2 orders of magnitude) in the cumulative total cases at 365 days (Table 1).

Effect of Intervention: Quarantine Only

A quarantine-only program can stop an outbreak of smallpox, but it takes a daily removal rate of at least 50% to ensure that disease transmission will cease. At a quarantine rate of 50% starting on day 30 postrelease, the daily number of new cases would peak at approximately 50 cases per day, with no new cases on day 240 and a cumulative total of approximately 2,300 cases (Figure 4). If 50% quarantine began 5 days earlier, on day 25 postrelease, the total cases would be approximately 1,750 and the maximum number of daily new cases would be 20 per day (Figure 4). A 15-day delay in starting quarantine programs, to day 45 postrelease, results in approximately 6,800 total cases and a maximum of almost 120 new cases daily (Figure 4).

5The number, severity, and cost of vaccine-induced side effects is the subject for a separate paper.

6Allowing 3 days for laboratory confirmation assumes that virus loads in clinical specimens may be insufficient to allow use of rapid assays and confirmation must await the results of a culture-based assay, which takes approximately 72 hours. Rapid laboratory confirmation, within 24 hours, is possible.
Effect of Intervention: Vaccination Only

A vaccination-only program that reduces the rate of transmission to 0.99 persons infected per infectious person will eventually stop an outbreak, but not within 365 days postrelease, even if it is begun on day 25 postrelease (Figure 5). To stop the outbreak by day 365 postrelease, a vaccination campaign starting on day 30 must reduce transmission to approximately 0.85 persons infected per infectious person (Figure 5), resulting in a cumulative total of 2,857 cases. If the same intervention were started on day 25 postrelease, the cumulative total would decline to 2,125 cases. Delaying the start of the intervention to day 45 postrelease would result in 3 new cases per day and a cumulative total of 8,347 cases on day 365.

Effect of Intervention: Quarantine and Vaccination

When combined with a quarantine rate of 25%, to stop transmission by day 365 postrelease, vaccination has to effectively reduce the rate of transmission by at least 33%, from 3 persons infected to 2 persons infected per infectious person (Figure 6). Although transmission will be halted, the total number of cases would be approximately 4,200, which is 82% greater than the total if a 50% daily reduction quarantine-only program is assumed (Figure 4). Starting on day 25 postrelease reduces the total number of cases to approximately 3,200 (Figure 6). Delaying the start of a combined intervention to day 45 postrelease increases the total number of cases to approximately 12,400.

Table 1. Estimates of cumulative total smallpox cases after 365 days with no intervention

| No. initially infecteda | No. infected per infectious personb | Cumulative total no. of smallpox cases, days postreleasec |
|-------------------------|------------------------------------|---------------------------------------------------------|
|                         |                                    | 30 days | 90 days | 180 days | 365 days |
| 10                      | 1.5                                | 31      | 214     | 2,190    | 224 thousand |
| 10                      | 3.0                                | 64      | 4,478   | 2.2 million | 774 billion |
| 1,000                   | 1.5                                | 3,094   | 21,372  | 219,006  | 22 million   |
| 1,000                   | 3.0                                | 6,387   | 447,794 | 222 million | 77 trillion |

aNumber initially infected refers to those who are exposed during a release so that they subsequently become infectious to others. This scenario excludes those who are exposed but either do not become ill (i.e., are immune or are not exposed to an infectious dose) or do not become infectious (residual immunity from prior vaccination may be sufficient to prevent onward transmission).

bThe number of persons infected per infectious person is the transmission rate.

cAssumes an unlimited supply of smallpox-susceptible persons.
Figure 5. Daily and total cases of smallpox for two vaccine-induced rates of transmission and three postrelease start dates. The graphs show that, while reducing the transmission rate to 0.99 persons infected per infectious person reduces the daily number of cases over the period studied, vaccination must reduce the rate of transmission to 0.85 persons infected per infectious person to stop the outbreak within 365 days postrelease. Data were generated by assuming 100 initially infected persons and an initial transmission rate of 3 persons infected per infectious person. For clarity, the graphs of daily cases do not include the assumed 100 initially infected. The graphs of total cases include those initially infected.

Effect of Intervention: Number of Infectious Persons Quarantined

With a quarantine-only intervention of 50% daily rate of removal, starting on day 30 postrelease, the peak number of daily removals is 69 infectious persons, occurring on day 30 (start day) with a cumulative total of 2,166 infectious persons quarantined. With a combination of a 33% vaccine-induced reduction in transmission and a 25% daily removal quarantine program, the peak number of daily removals is 34 (start day 30), but the cumulative total that must be quarantined is approximately 3,970 infectious persons.

Sensitivity Analyses: Effect of Changing Input Values

Reducing the transmission rate to 2 results in a quarantine-only program with a 25% daily removal rate almost stopping transmission (Table 2). Delaying the start of such an intervention to day 45 but combining it with a vaccination campaign, which reduced transmission by 33%, would halt the outbreak by Day 365 (Table 2). For the same intervention start date, increasing the assumed transmission rate from 2 to 5 persons infected per infectious person does not proportionately increase the cumulative total number of cases at day 365. Even with a quarantine rate of 25% removal per day, assuming that vaccination concurrently reduces transmission by 66%, the cumulative total number of cases on day 365 is 19,821 (Table 2). For any given scenario, increasing the number initially infected from 100 to 1,000 increases both the cumulative totals and the daily number of new cases at day 365 by a factor of 10 (Table 2). Similarly, reducing the number of those initially infected from 100 to 10 would cause a proportionate reduction in both cumulative totals and daily numbers (data not shown; additional results in Appendix II, available at URL: http://www.cdc.gov/ncidod/dw/vol7no6/meltzer_appendix2.htm).

Sensitivity Analyses: Minimum Levels of Intervention to Achieve Target Days

The earlier the target date for stopping an outbreak, the larger the minimum vaccine-induced reduction in transmission needed to achieve zero transmission (i.e., outbreak stopped). For example, assuming a transmission rate of 3 and a 25% daily removal rate, a target date of day 225 requires a 45.2% vaccine-induced reduction in transmission to 1.65 persons infected per infectious person (Table 3). Reducing the target date to day 75 requires a 76.7% vaccine-induced reduction in transmission to 0.70 persons infected per infectious person (Table 3). Again, delay in starting interventions makes it notably more difficult to stop an outbreak by a given target date. For example, to achieve a target date of day 75 with a 50% daily removal rate, starting interventions on day 45 requires a vaccine-induced reduction in transmission of 81.2%, to 0.57 persons.
Table 2. Sensitivity analyses: Effect on number of cases of smallpox due to variations in numbers initially infected, numbers infected per infectious person, intervention start days, and quarantine and vaccination effectiveness

| No. initially infected | No. infected per infectious | Start day | Quarantine % removal per day | Vaccination: % reduction in transmission | Impact: Cumulative total at 365 days | Impact: Daily cases at 365 days | Increase or decrease (+/-) |
|------------------------|----------------------------|-----------|----------------------------|--------------------------------|-----------------------------------|-------------------------------|---------------------------|
| Base: 100              | 3.0                        | 30        | 25                         | 33                             | 4,421                             | 3                            | -                         |
| 100                    | 2.0                        | 30        | 25                         | Nil                            | 2,455                             | 2                            | -                         |
| 100                    | 2.0                        | 30        | 10                         | 25                             | 10,512                            | 2                            | -                         |
| 100                    | 2.0                        | 45        | 25                         | 33                             | 1,548                             | 0                            | -                         |
| 100                    | 5.0                        | 30        | 25                         | 66                             | 4,116                             | 0                            | -                         |
| 100                    | 5.0                        | 45        | 25                         | 66                             | 19,821                            | 1                            | -                         |
| 1,000                  | 2.0                        | 30        | 10                         | 25                             | 105,117                           | 511                          | +                         |
| 1,000                  | 2.0                        | 30        | 10                         | 33                             | 32,125                            | 42                           | -                         |

Note: Table 1, Appendix II (see online) is an expanded version of this table.

1Number initially infected refers to those who are exposed during a release such that they become infectious. This excludes those who are exposed but either do not become ill or do not become infectious.
2The number of persons infected per infectious person is the transmission rate.
3Start day, for both quarantine and vaccination interventions, refers to the day postrelease, with the day of release being day 1.
4Quarantine refers to removal of infectious persons only, starting on the first day of overt symptoms (i.e., rash). At a 25% daily removal rate, a cohort of all those entering the first day of overt symptoms is entirely removed in 17 days (18 to 20 days post-incubation) after day 1 of overt symptoms, with 90% removed in 9 days. At a 10% daily removal, a cohort of all those entering the first day of overt symptoms is entirely removed in 44 days (45 to 47 days post incubation) after day 1 of overt symptoms, with 90% removed in 22 days.
5Vaccination is assumed to reduce the transmission rate by a given percentage (e.g., 25% reduction results in transmission declining from 2.0 to 1.5 persons infected per infectious person, and 33% reduces transmission from 2.0 to 1.32).
6(+/-) = an increasing rate of daily cases on day 365, and thus the modeled interventions will not stop the transmission of smallpox. (-) = a decreasing rate of daily cases, such that the interventions modeled will eventually stop the transmission of smallpox.

See Figure 6 for complete results related to the base case in the initial modeling scenario.
infected per infectious person (Table 3). If a 25% quarantine-induced daily removal rate is assumed, then vaccination must reduce transmission by 91.5% to 0.26 persons infected per infectious person (Additional results in Appendix II, available at URL: http://www.cdc.gov/ncidod/eid/vol7no6/melter_appendix2.htm).

Vaccinations per Case: Stockpile Issues

We identified 14 outbreaks in which a range of 9 to 102,857 persons were vaccinated per case of smallpox (Table 4). The mean was 14,411 persons vaccinated per case (median 2,155). When fitted to a Gamma probability distribution (35), the 95th, 90th, and 10th percentiles were 7,001, 4,329, and 3.5 doses per case, respectively (Table 4).

In Yugoslavia the number vaccinated per case was approximately 5 times greater than in any other outbreak considered (31). If the Yugoslavia data are removed from the data set (Table 4), the simple average doses per case would be 6,370 (56% decrease), with a median value of 1,801 (16% decrease) doses per case.

If one assumes 4,200 cases result from 100 index cases and a combined quarantine and vaccination program (start day 30: Figure 6), and one uses a median of 2,155 persons vaccinated per case (Table 4), 9,051,000 doses must be made available for use (4,200 x 2,155). The 95th, 90th, and 5th percentiles of this estimate are 29,404,200, 18,181,800, and 14,700, respectively. When the assumed number of persons infected per infectious person is set at 2, the number of cases declines to 1,548 (start on day 45: Table 2), and 3,335,940 vaccine doses must be made available for use (2,155 x 1,548), with 95th, 90th, and 5th percentiles of 10,837,548, 6,701,292, and 5,418, respectively.

Discussion

The greatest simplification in building our model was the assumption that the supply of susceptible persons was unlimited, so that any specified rate of transmission would be sustained for at least 365 days. In reality, many factors, such as existing immunity and behavior modifications by society (e.g., voluntary or forced quarantine) could limit the supply of susceptible persons, reducing the total number of cases in a 1-year period.

Supply of susceptible persons and assumed rate of transmission are the most important variables influencing the total number of smallpox cases (Tables 1,2). Historically, average transmission rates were well below three persons infected per infectious person (Appendix I, available at URL: http://www.cdc.gov/ncidod/eid/vol7no6/melter_appendix1.htm). Variables that can affect the average rate of transmission of smallpox include seasonality, group size, and type of contact (“face-to-face” or “incidental”; Appendix I, Table 5). Our model does not explicitly allow for consideration of such variables, and adjustments to transmission rate resulting from changes in factors such as group size must be done externally to the model.

Another result of assuming an unlimited supply of susceptible persons is that the impact of multiple releases does not “need” to be explicitly modeled. That is, in our model it does not matter if the release initially infects 100 persons who are standing shoulder to shoulder or are each separated by 500 miles. The two variables that can be manipulated to act as proxies for modeling the impact of multiple releases

| Target stop day | Start day of interventions | Numbers infected per infectious person | Quarantine: Minimum % removal per day | Vaccination: Minimum % reduction in transmission |
|-----------------|---------------------------|---------------------------------------|---------------------------------------|-----------------------------------------------|
| 75              | 30                        | 2                                     | 25.0                                  | 58.0 (0.84)                                   |
| 75              | 30                        | 3                                     | 25.0                                  | 76.7 (0.70)                                   |
| 75              | 30                        | 5                                     | 50.0                                  | 78.9 (1.06)                                   |
| 75              | 45                        | 3                                     | 50.0                                  | 81.2 (0.57)                                   |
| 150             | 30                        | 2                                     | 25.0                                  | 25.8 (1.49)                                   |
| 150             | 30                        | 3                                     | 25.0                                  | 53.7 (1.39)                                   |
| 150             | 30                        | 5                                     | 50.0                                  | 55.7 (2.22)                                   |
| 150             | 45                        | 3                                     | 50.0                                  | 33.3 (2.00)                                   |
| 225             | 30                        | 2                                     | 25.0                                  | 14.3 (1.72)                                   |
| 225             | 30                        | 3                                     | 25.0                                  | 45.2 (1.65)                                   |
| 225             | 30                        | 5                                     | 50.0                                  | 46.5 (2.68)                                   |
| 225             | 45                        | 3                                     | 50.0                                  | 14.8 (2.56)                                   |

See Appendix II, Table 2 (online) for an expanded version of this table.

\[\text{Target stop day and start day of interventions refer to days postrelease, with day of release being day 1.}\]

\[\text{The number of persons infected per infectious person is the transmission rate.}\]

\[\text{Quarantine refers to removal of infectious persons only, starting on the first day of overt symptoms (i.e., rash). Rates are the minimum rates needed, when combined with vaccination, to ensure that there is zero transmission by the target date. At a 25% daily removal rate of infectious persons, a cohort of all those entering their first day of overt symptoms is entirely removed in 17 days (18-20 days postincubation) after day 1 of overt symptoms, with 90% removed in 9 days. With 50% daily removal of infectious persons, a cohort of all those entering the first day of overt symptoms is entirely removed in 7 days (8 to 10 days postincubation) after day 1 of overt symptoms, with 90% removed in 4 days.}\]

\[\text{Vaccination assumed to reduce the transmission rate by a given percentage (e.g., 25% reduction results in transmission declining from 3.0 to 2.25 persons infected per infectious person). Percentages are the minimum percentage reduction in the assumed rate of transmission needed, when combined with quarantine, to ensure zero transmission by the target date. The resultant transmission rate, after reduction, is in parentheses.}\]
first, what percentage of the population is truly susceptible to smallpox and could become infectious to others; and second, how would these susceptible persons interact with those infected?\(^8\)

**Vaccination Alone or Combined with Quarantine?**

The results from the model demonstrate that it is theoretically possible to completely halt the spread of smallpox by quarantine only (Figure 4; Tables 2,3). The level of quarantine needed, however, may prove impossible to enforce. On the other hand, historically, mass vaccinations alone did not always stop the transmission of smallpox (7,8). Thus, relying solely on either intervention would appear to be unwise, so that a combination of vaccination and quarantine should be used.

Using quarantine has the benefit of lowering the level of effective vaccination needed to stop transmission (Tables 2,3). Furthermore, compared with a vaccination-only intervention, a combined quarantine and vaccination campaign will produce fewer total cases and stop transmission sooner (Table 3). Depending on how vaccination is done, requiring a lower level of effective vaccination could result in fewer vaccinations being administered. Given that the smallpox vaccine occasionally has adverse effects, including death (7,8), any method that reduces the number of vaccinations needed to halt transmission should be examined for possible inclusion into a response plan.

**Doses To Be Stockpiled**

The number of estimated doses that must be stockpiled ranges from the 5th percentile estimate of approximately 5,000 doses (assuming approximately 1,500 cases) to a 95th percentile of almost 30 million (assuming approximately 4,200 cases). The latter estimate was generated by assuming an average rate of transmission of three persons infected per infectious person. This assumed level of transmission is well above historical average rates of transmission (Appendix I, available at URL: http://www.cdc.gov/ncidod/ed/evol7no6/meltzer_appendix1.htm). Thus, allowing for factors such as vaccine wastage, stockpiling 40 million doses as recommended by Henderson et al. (5) should be adequate.

---

\(^8\)Although there are some historical data regarding how infected persons interacted and infected others, all such data were collected when circumstances differed from those of today’s societies, particularly with regard to travel and spread of information. Although air and other modes of mass travel were common before smallpox was eradicated, the numbers of travelers and the total miles traveled have vastly increased in the past 30 years. Similarly, although mass media were well known and used in the 1960s and 1970s, more outlets are available to spread information than ever before. It is unknown how these and other changes could affect the spread of smallpox.
Because the pool of smallpox-susceptible persons is now very large, the rate of transmission may be much higher than historical averages, resulting in more cases of smallpox and the need for more vaccine doses stockpiled. For example, if a transmission rate of 5 is assumed and large-scale interventions are started on day 45 postrelease, the 95th percentile of doses that should be stockpiled is 140 million doses (mean 43 million doses; Tables 2,4). Similar estimates are obtained if it is assumed that 1,000 persons are initially infected (Tables 2, 4). Further supporting the argument for stockpiling 40 million doses is the idea that there would be enormous public demand for vaccination in the event of an outbreak.

Stockpiling a large number of doses of smallpox vaccine has three major problems. Building a stockpile of 140 million doses might leave public health officials without needed resources to prepare for and implement other interventions, such as quarantine and public education. Second, a large stockpile poses the problem of deciding how to use it. Investing in such a resource may invite the conclusion that the only suitable response to a deliberate release of smallpox would be a mass vaccination campaign, using as much of the stockpile as possible. An enormous logistical problem would be associated with rapidly vaccinating 140 million persons. Assuming 10 minutes per person vaccinated (excluding patient waiting time), 23 million person-hours would be required to vaccinate 140 million people. In 1947 in New York City it took approximately 1 week to vaccinate 6 million people in response to an outbreak with eight cases (1). An additional problem with trying to mass-immunize >100 million people is that, if a transmission rate of 5 is assumed, disease spread might be so rapid as to "outrun" any mass vaccination attempt (Tables 1,2). The third problem associated with a large stockpile of smallpox vaccine is that a large number of side effects would be generated, including need for treatment with vaccinia immunoglobulin and deaths as a result of adverse reactions (26). Between the demands of vaccination and treatment of side effects, the health-care system would be overburdened, to the detriment of treatment for any other disease or medical emergency.

Policy Implications

The four most important policy implications from the model results are 1) Delay in intervention will be costly, dramatically increasing the total number of cases; 2) Postrelease intervention should be a combination of quarantine and vaccination; 3) Planning requires not only an appreciation of how many persons may be infected initially, but also an understanding of the likely rate of transmission; and 4) a stockpile of approximately 40 million doses of vaccine should be adequate.

Beyond stockpiling, adequate planning, preparation, and practice must be carried out (36). Such preparation must include training health-care workers to recognize a case of smallpox and what to do if a case is diagnosed. Public health authorities and policymakers need to make detailed plans that fully describe how persons will be quarantined and how quarantine will be enforced. The successful enforcement of quarantine requires political will, public acceptance, and group discipline. Thus, a large part of the preparation for a public health response to smallpox as a bioterrorist weapon must involve educating policymakers and the public as to why quarantine is needed and why relying solely on mass immunizations may not be the magic bullet that some might hope.

Dr. Meltzer is senior health economist, National Center for Infectious Diseases, Centers for Disease Control and Prevention. His research interests focus on assessing the economics of public health interventions such as oral raccoon rabies vaccine, Lyme disease vaccine, influenza vaccination among healthy working adults, and the economics of planning, preparing and practicing for the next influenza pandemic. He uses a variety of research methodologies, including Monte Carlo models, Markov models, contingent valuation (willingness-to-pay) surveys, and nonmonetary units such as Disability Adjusted Life Years.

References

1. Henderson DA. The looming threat of bioterrorism. Science 1999;283:1279-82.
2. Henderson DA. Smallpox: Clinical and epidemiologic features. Emerg Infect Dis 1999;5:537-9.
3. O'Toole T. Smallpox: An attack scenario. Emerg Infect Dis 1999;5:540-6.
4. Bartlett J. Aftermath of a hypothetical smallpox disaster. Emerg Infect Dis 1999;5:547-51.
5. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jerning PJ, et al. Smallpox as a biological weapon: Medical and public health management. JAMA 1999;281:2127-37.
6. Rao AR. Smallpox. Bombay: The Kathari Book Depot; 1972.
7. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization; 1988.
8. Dixon CW. Smallpox. London: Churchill; 1982.
9. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. New York: Oxford University Press; 1991.
10. Anderson RM, May RM. Population biology of infectious diseases: Part I. Nature 1979;280:455-61.
11. Cliff AD, Haggett P. Statistical modeling of measles and influenza outbreaks. Stat Methods Med Res 1993;2:43-73.
12. Anderson RM, May RM. Population biology of infectious diseases: Part I. Nature 1979;280:361-7.
13. Anderson RM. Transmission dynamics and control of infectious diseases agents. In: Anderson RM, May RM, editors. Population biology of infectious diseases: Part II. Nature 1979;280:455-61.
14. Aron J, May RM. The population dynamics of malaria. In: Anderson RM, editor. The population dynamics of infectious diseases: theory and application. London: Chapman and Hall; 1982.
15. Fraenenthal JC. Smallpox: When should routine vaccination be discontinued? The UMAP Expository Monograph Series. Boston: Birkhäuser; 1981.
16. Giordano FR, Weir MD, Fox WP. A first course in mathematical modeling. 2nd ed. Pacific Grove, CA: Brooks/Cole Publishing Company; 1997.
17. Christie AR. Infectious diseases: Epidemiology and clinical practice. 3rd ed. New York: Churchill Livingstone; 1980.
18. Singh S. Some aspects of the epidemiology of smallpox in Nepal. Geneva: World Health Organization (WHO/SE/69.10); 1969.
19. Mack TM. Smallpox in Europe, 1950-1971. J Infect Dis 1972;125:161-9.
20. U.S. Bureau of the Census. Statistical abstract of the United States: 1999. 119th ed. Washington: Bureau of the Census; 1999.
21. Royal Commission on Vaccination. A report on vaccination and its results, based on evidence taken by the Royal Commission during the years 1889-1897. Vol 1. The text of the commission report. London: New Sydenham Society; 1898.
22. Smith ADM. Epidemiological patterns in directly transmitted human infections. In: Croll NA, Cross JH, editors. Human ecology and infectious diseases. New York: Academic Press; 1983. p. 333-51.
23. Barlett MS. Measles periodicity and community size. J Royal Stat Soc Series A 1957;120:48-60.
24. Bartlett MS. Critical community size for measles in the United States. J Royal Stat Soc Series A 1960;123:37-44.
25. Arita I, Wickett J, Fenner F. Impact of population density on immunization programmes. J Hyg Camb 1986;96:459-66.
26. Lane J M, Millar J D. Routine childhood vaccination against smallpox reconsidered. N Engl J Med 1969;281:1220-24.
27. Pattanayak S, Sehgal PN, Raghavan NGS. Outbreaks of smallpox during 1968 in some villages of Jaipur district, Rajasthan. Geneva: World Health Organization (WHO/SE/70.20); 1970.
28. de Sario V. Field investigation of an outbreak of smallpox at Bawku, Ghana: May-October, 1967. Geneva: World Health Organization (WHO/SE/69.24); 1969.
29. Rangaraj AG. An outbreak of smallpox in a village in Afghanistan. Geneva: World Health Organization (WHO/SE/69.9); 1969.
30. Glokpor GF, Agle AN. Epidemiological investigations. Smallpox Eradication Programme in Togo: 1969. Geneva: World Health Organization (WHO/SE/70.21); 1970.
31. Litvinjenko S, Arsic B, Borjanovic S. Epidemiologic aspects of smallpox in Yugoslavia in 1972. Geneva: World Health Organization (WHO/SE/73.57); 1973.
32. de Costa EA, Morris L. Smallpox epidemic in a Brazilian community. Geneva: World Health Organization (WHO/SE/74.64); 1974.
33. Presthus GT, Sibiya JB. A persistent focus of smallpox in Botswana. Geneva: World Health Organization (WHO/SE/74.89); 1974.
34. Great Britain Ministry of Health. Smallpox, 1961-62. Reports on public health and medical subjects, No. 109. London: Her Majesty's Stationery Office; 1963.
35. Evans M, Hastings N, Peacock B. Statistical distributions. 2nd ed. New York: John Wiley & Sons, Inc.; 1993.
36. Kaufmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack: Are prevention and postattack intervention programs justifiable? Emerg Infect Dis 1997;3:83-94.
Modeling Potential Responses to Smallpox as a Bioterrorist Weapon

Appendix I: A Mathematical Review of the Transmission of Smallpox

Martin I. Meltzer,* Inger Damon,* James W. LeDuc,* and J. Donald Millar†

*Centers for Disease Control and Prevention, Atlanta, Georgia, USA;
†Don Millar & Associates, Inc., Atlanta, Georgia, USA

The mathematical model we described requires the researcher to preset the average number of disease-susceptible persons infected by an infectious patient (i.e., the rate of transmission). To obtain historical data describing the average number of persons infected per infectious person, we examined the literature for data regarding the rate of transmission. Since there are already a number of excellent reviews of smallpox epidemiology (1-3), we reviewed and reported only papers in which transmission rate was specifically measured or sufficient data were provided for it to be calculated.

Methods

We reviewed both published and unpublished papers, books, and reports to compile a set of tables containing data related to the rate of transmission of smallpox. We did not use computerized medical literature databases as the primary means to identify reports and papers because such databases typically do not catalog published papers before 1950, when smallpox was common. Further, such databases do not typically catalog unpublished reports and papers with limited distribution. This last limitation excludes many reports written by epidemiologists working for the World Health Organization (WHO) and other public health organizations during the smallpox eradication program.

We considered data that used at least one of three possible methods to measure rate of transmission: using a mathematical formula to derive the transmission rate from data describing the percentage of susceptible persons that must be vaccinated to eradicate the disease (i.e., stop transmission); examining data regarding the attack rate among susceptible persons for a given period; and evaluating data reporting the number of persons directly infected by an infectious person. These methods progress from the most indirect to the most direct. The data produced by the methods, therefore, may progress from the least to the most exact measurement of the rate of transmission of smallpox.

Review of the Data

Rate of Transmission as Measured by Percentage of Population Vaccinated Needed for Eradication
The larger the percentage of a susceptible population that must be vaccinated to eradicate a
disease, the relatively more infectious the disease. Anderson and May (4) present the following
equation for calculating the critical or minimal proportion of a population that must be
immunized for eradication to be achieved:

\[ p_c = 1 - \left( \frac{1}{R_o} \right) \]

where \( p_c \) is the critical proportion and \( R_o \) is the basic reproductive rate of a parasite. \( R_o \) is
essentially the average number of offspring that a parasite (a term that includes macro- and
microparasites) can produce. For a parasite to continue to survive, \( R_o > 1 \). For a microparasite
such as the variola virus that causes smallpox, \( R_o \) is more precisely defined as the average
number of secondary infections produced when one infectious individual is introduced into a
population of susceptible hosts (4).

Using the above equation and data from a variety of sources, Anderson and May presented
estimates of the critical value \( p_c \) for 10 diseases (Table 1). However, exactly how the value of \( p_c \)
for smallpox was calculated is unclear because the lack of published mathematical models
describing the spread of smallpox has resulted in a lack of readily available published estimates
of the value of \( R_o \) for smallpox. The upper estimate of 80% of the susceptible population that
must be vaccinated to eradicate smallpox (Table 1) may have come from a WHO
recommendation published in 1967 (1,5). The mathematical reasoning behind such a
recommendation is not clear. History showed that actually vaccinating 80% of susceptible
persons does not necessarily cause smallpox to disappear from a population. In Asia, particularly
India, even when apparently80% of the population was vaccinated, outbreaks still occurred (2).
One reason why vaccinating 80% of the population may not have halted the spread of smallpox
is that the value of \( R_o \) for smallpox, and thus \( p_c \), may vary with density of susceptible populations
(4,6).

| Disease         | Critical percentage of susceptible persons that must be vaccinated to eradicate a disease (% of susceptible persons) |
|-----------------|--------------------------------------------------------------------------------------------------|
| Measles         | 90-95                                                                                           |
| Pertussis       | 90-95                                                                                           |
| Fifth\(^a\)     | 90-95                                                                                           |
| Chickenpox      | 85-90                                                                                            |
| Mumps           | 85-90                                                                                            |
| Rubella         | 82-87                                                                                            |
| Poliomyelitis   | 82-87                                                                                            |
| Diphtheria      | 82-87                                                                                            |
| Scarlet fever   | 82-87                                                                                            |
| Smallpox        | 70-80                                                                                            |
Fifth disease is caused by human parvovirus infection.
Adapted from Anderson and May (4), p. 88.

The failure to stop smallpox transmission when 80% of the population was vaccinated against the virus led to a 1964 WHO expert committee recommendation that the goal of the smallpox eradication campaign must be to vaccinate 100% of the population (7); however, that goal was difficult if not impossible to achieve in India. In 1973, the strategy was changed, with emphasis on surveillance to detect and then contain outbreaks of smallpox. This strategy and its variants worked so well that by 1977 India was officially declared free of smallpox (7).

There have also been recorded instances when smallpox disappeared even though <80% of the population was vaccinated. For example, in 1968, Sierra Leone had the highest incidence of smallpox in the world; yet the disease disappeared in 1969 when only 66% of the population had been vaccinated (8). Similarly, smallpox disappeared in Mali when only 51% of the population was vaccinated (8). In these and other West African countries, one reason that smallpox disappeared without ≥80% of the susceptible population being immunized is that the eradication program shifted to a policy of focusing on controlling outbreaks. Each outbreak was promptly investigated, and all the susceptible population surrounding the reported case(s) was vaccinated (i.e., a "ring" vaccination policy) (8).

**Rate of Transmission as Measured by Attack Rates among Susceptible Populations**

Data collected from an outbreak of smallpox in Sheffield, England, >100 years ago can be used to demonstrate both the attack rate of smallpox and the risk factors associated with infection (Table 2). The investigators found that persons with a history of vaccination or immunity (generally defined as having a visible vaccination scar or a history of a clinical case of smallpox) had attack rates 60% to 96% lower than those of persons without a history of vaccination (Table 2).

The attack rates among the unvaccinated "general population" are approximately 87% lower than those among the unvaccinated who lived in the same house as a person with a previously confirmed case. In other words, the most susceptible population was unvaccinated persons who lived in close proximity to a smallpox patient. From Table 2, we can conclude that smallpox in Sheffield was not readily spread among the general population by brief, casual encounters, such as walking down the street beside an ill person or briefly being in the same shop or business. Rather, smallpox was primarily spread among persons living in the same house as a smallpox patient. One can only guess how crowded the average living conditions were in the industrial town of Sheffield in the late Victorian era.

Table 2. Attack rates of smallpox among the general population and those living in houses with a case(s) of smallpox, Sheffield, England, 1887-88

| Population and age group | Attack rates (%) |
|--------------------------|-----------------|
|                          |                 |
### Table 3. Attack rates of smallpox among the general population and those living in houses with a smallpox patient(s)

| Site                                      | Year    | total population | susceptible persons in house | nonsusceptible persons in house | Ref. |
|-------------------------------------------|---------|------------------|-------------------------------|--------------------------------|------|
| Bengal, Bangladesh b                       | 1967    | 0.2-0.5c         | 36                            | 12                              | 10-12|
| Campo Alegre, Brazil                      | 1968-69 | 27               | 79                            | 2                               | 13   |
| Gerere hamlet, Nigeria d                  | 1968    | 30               | 52                            | 2                               | 14   |
| Pirapitinga, Brazil                       | 1969    | 25               | 65                            | 0                               | 13   |
| Nellore district, Andrapradesh, India e   | 1969    | 5.3-23           | 40                            | 8.5                             | 15   |
| Madras, India                             | 1968    | n/a f            | 20                            | 2                               | 16   |
| Rural Afghanistan                         | 1969    | n/a g            | 50                            | 0                               | 17   |
| Punjab Province, West 1968-70             | 1968-70 | n/a g            | 70 h                          | 5 h                             | 18   |
| Pakistan                                  | 1969    | n/a g            | 69                            | 3                               | 19   |
| Brazil l                                  | 1969    | 12               | 68                            | 3.5                             | 20   |
| Utinga City, Brazil                       | 1969    |                  |                               |                                 |      |

*Non-susceptible persons include those with evidence of vaccination (e.g., scar) or history of a clinical case of smallpox, who thus were naturally immunized.*

*Known as East Pakistan when the data were collected (10).*

*The attack rate depended on population density, with the lowest attack rates in villages with...*
baris (a group of patrilineally related families) described as "scattered" and the highest rates in villages with baris described as "compact" (10).

*The source (14) did not analyze the village population by household, and thus the result presented is the average for all susceptible persons throughout the village. However, the total population of the village at the time of the outbreak was 203.

This reference documented outbreaks in seven small villages (15). The results are the range of attack rates measured in the villages.

The source did not provide an estimate of the total population where the outbreaks occurred but did note that in the city of Madras 3,000 to 4,000 cases occurred annually until the Smallpox Eradication Programme began in 1963. Subsequently, 725, 75, 38, and 25 cases were reported in 1965, 1966, 1967, and the first half of 1968, respectively.

These studies did not provide a denominator that would permit total population attack rates to be calculated.

The source did not identify individual cases in individual houses, but calculated the average secondary attack rate among vaccinated and unvaccinated "family contacts" of index cases.

The source reports data from 33 outbreaks in five provinces in Brazil, with 27 outbreaks in rural areas and six in urban areas.

The data refer to cases only in Utinga city. Additional cases occurred in the surrounding municipality (20).

**Rate of Transmission as Measured by the Number of Persons Infected by an Infectious Person**

Using data from a number of different outbreaks around the world during the 1960s and early 1970s, we estimated the number of persons directly infected by an infectious person (Table 4). Most reports cited had an average of <2 persons infected per infectious person (Table 4), but there was a wide range in numbers. In all outbreaks, some infected persons apparently did not transmit a symptomatic case of smallpox to another person. The upper estimates of number infected per infectious person vary widely, from 38 in Yugoslavia (27) to 1 in West Bromwich, United Kingdom (29). The average numbers of persons infected per infectious person range from 0 to 8, with most outbreaks recording an average of <1 person infected per infectious person (Table 4).

**Table 4. Number of persons directly infected by an infectious case of smallpox**

| Site                        | Year and duration of outbreak | Total no. of cases | Range | Mean | Ref. |
|-----------------------------|------------------------------|--------------------|-------|------|------|
| Erode, Tamil Nadu, India    | 1969; 2.5 months             | 6                  | 0-3   | 1    | 21   |
| Visalur, Tamil Nadu, India  | 1969; 1 month                | 1                  | 0     | 0    | 21   |
| Bengal, East Pakistan       | 1967;                        | 20\(^c\)           | 0-2.3 | 0.8  | 10   |
| Location                        | Duration | Cases (n) | Generations | Cases/Generation | References |
|--------------------------------|----------|-----------|-------------|------------------|------------|
| Campo Alegre, Brazil           | 12 months| 74        | n/a         | 2.1              | 13         |
| Gerere hamlet, Nigeria         | 10 months| 12        | n/a         | 2                | 14         |
| Kathmandu Valley, Nepal        | 4 months | 47        | 0-7         | 2.75             | 22         |
| Chingleput district, Madras, India |        | 47        | 0-9         | 0                | 16         |
| Madras, India                  | 1968     | 25        | 0-4         | 0.48             | 23         |
| Bawku district, Ghana          | 1967     | 66        | 0-11        | 0.9              | 24         |
| Punjab District, West Pakistan | 1968-70  | 138       | n/a         | 1.25             | 18         |
| Loralai District Pakistan      | 1971     | 23        | 0-9         | 2                | 25         |
| Botswana                       | 1973     | 30        | 0-3         | 0.78             | 26         |
| Yugoslavia                      | 1972     | 175       | 0-38        | 8-11             | 27         |
| Meschede Hospital, Germany     | 1970     | 20        | 0-17        | 0.95             | 28         |
| London, UK                     | 1961     | 3         | 0-2         | 0.66             | 29         |
| West Bromwich, UK              | 1961     | 2         | 0-1         | 0.5              | 29         |
| Bradford, UK                   | 1961     | 14        | 0-10        | 0.9              | 29         |
| Birmingham, UK                 | 1962     | 1         | 0           | 0                | 29         |
| Cardiff, UK                    | 1962     | 47        | 0-18        | 0.97             | 29         |
| Toffo-Gare, Dahomey            | 1967     | 28        | 0-4         | 0.93             | 30         |

*aTotal number of cases includes the index patients who spread the disease to others.

bEast Pakistan is now called Bangladesh.

cIn the area studied, for the time reported, there were 119 cases in 30 outbreaks. However, data regarding the number of "introducers" and the number of first-generation cases associated with those introducers were limited to 20 cases (11 introducers, 9 first-generation cases).

dThe source (13) provided only the total number of primary or coprimary cases and total number of secondary cases. Thus, only an average number of cases per infectious person can be calculated.

eThe total number of reported cases was 62. However, the reported average was calculated from a subset of 12 cases in a single compound of 24 people who lived in the village where the outbreak occurred. The source (14) reported the total number of generations (6) and the total number of cases in the compound, but not the actual cases per generation.

fAlthough the source reported 13 outbreaks resulting in 47 cases, the source of infection could be traced in only four outbreaks. Further, the source did not report generations, only "subsequent cases," which may be a single generation or more. Thus, the upper range of 7 cases per infectious case may be an overestimate.

gThe source reported 47 cases but only specifically identified transmission (who infected whom) of one patient admitted to an infectious disease hospital in Madras. This patient, despite being sick at home for nearly 8 days, did not infect anyone else.

hThe source did not specify the number of index cases, although the authors reported data for 47
outbreaks, resulting in 70 first-generation and 21 second-generation cases. Our assumption that there was a single index case per outbreak maximizes the calculated average transmission rate.  

The source reported that four second-generation cases infected eight third-generation cases. However, among these cases, the authors did not describe who infected whom. Therefore, the average was calculated by assuming that just one of the second-generation cases infected all eight third-generation cases. This assumption maximizes the calculated average transmission rate.

This is a weighted average, based on the report of 11 first-generation cases, 140 second-generation cases, and 23 third-generation cases. Thus, the average first to second generation was 13 cases per infectious person, and the average second to third generation was 0.2 cases per infectious person. However, since one first-generation case caused 38 second-generation cases (reputedly the largest reported number of infections known to have been caused by a single patient) and another first generation caused 16 second-generation cases, there must have been a number of first- and second-generation cases that did not infect any others. Removing these two first-generation cases and the second-generation case attributed to them, the weighted average becomes 8 (11 first generation, 86 second generation, and 23 third generation).

Although one patient infected 17 others, only two other patients infected one case each. The other 17 patients did not transmit smallpox to others.

Since transmission was eventually halted in all the outbreaks (Table 4), most outbreaks have an average transmission rate for the entire outbreak of <1 person infected per infectious person. A more detailed examination of the data from six of the outbreaks is presented in the Figure, which presents the frequency of persons infected per infectious person over time (generation of disease). The average rate of transmission per generation ranges from 0.47 persons infected per infectious person (third to fourth generation) to 1.48 (index cases to first generation) (Figure). The overall rate of transmission in the six outbreaks was 0.47. In any given generation, there is a wide range in the number of persons infected per infectious person, ranging from zero (occurring in all generations) to as high as 11 or even 18 (the latter occurring in the graph depicting transmission from the fourth to fifth generation).
Figure. Frequency, by generation of disease, of the number of persons infected with smallpox by an infectious person. Average refers to the mean number of persons infected. Not all sources reported five generations of disease. In some instances, the reported outbreak was contained or died out before the fifth generation (23-26,29,30).
Further evidence of the relative difficulty for one person to infect (i.e., explaining low transmission rates) is found in data representing the contacts of the last case of naturally occurring smallpox on earth (31; Table 5). The contacts are persons who visited the patient at his home when he first developed a fever (prodromal stage), who had contact with him after he was admitted to a hospital (but before he developed a rash), and who visited him at his home after he was initially discharged (with a rash) with a diagnosis of chickenpox. Of the 161 persons who had contact with him, at least 12 unvaccinated persons had "face-to-face" contact yet did not subsequently become ill with clinical cases of smallpox.

More evidence that sustained close contact is typically needed for transmission is provided by data from the 1972 Yugoslavian outbreak, in which 84 of 175 patients contracted the disease while in the hospital with a smallpox patient (27). One patient, who spent time in three different hospitals, infected 38 people, probably a record number directly infected by a single person. Close, sustained contact in a hospital, probably through a connected ventilation system, also permitted one patient in Meschede Hospital, Germany, to directly infect 17 others (28).

Table 5. Number, type of exposure, and vaccination status of possible contacts of the last recorded human smallpox case in the worlda

| Vaccination status at exposure | Face-to-face | Incidental | Total |
|-------------------------------|-------------|------------|-------|
| Within past 3 years           | 58          | 62         | 120   |
| >3 years previously           | 21          | 8          | 41    |
| Unvaccinated                  | 12          | 70         | 161   |
| Totals                        | 91          |            |       |

aAli Maow Maalin was the last human on earth to have been diagnosed, in October 1977, with a naturally occurring case of smallpox. Although he had numerous contacts with both vaccinated and unvaccinated persons, none of the contacts had overt, clinical smallpox (31).

Conclusions

Although smallpox cases were recorded throughout human history until its eradication in the 1970s, remarkably few data are available that allow us to calculate the transmission rate of smallpox. Understanding the possible transmission rate of smallpox after a deliberate release of the virus is crucial to developing estimates of impact suitable for policy planning purposes. We therefore evaluated data that potentially measured the rate of transmission by three possible methods.

The first, and possibly most indirect, method was to examine estimates of vaccination coverage needed to eradicate smallpox. We found, however, that the available data do not contain sufficient information regarding the transmission rate of smallpox suitable for modeling an
outbreak. Experiences from the field appear to differ distinctly from theoretical estimates. These differences stand in contrast to the experience gained from the use of vaccines to control rubella and measles. For these diseases, vaccination levels must be >90% for disease to be eliminated (32,33; Table 1). The overall conclusion from the data regarding estimates of vaccination coverage needed to eradicate smallpox is that the epidemiology of smallpox differs notably from that of other infectious diseases (1,34; Table 1).

The second method of measuring rate of transmission was to consider data relating to the attack rates. We noted, however, that attack rate can vary by time, population, and residence of a susceptible person in the same house as an infectious person (Tables 2, 3). We therefore conclude that the use of attack rates derived by simply dividing the number of cases of smallpox by the total population can often be an inadequate measure of the rate of transmission of smallpox. In the report describing the Sheffield data (Table 2), average attack rates range from 1.9% (Sheffield, 1887-88) to as low as 0.2% (Leicester, 1892-93) (9). Attack rates may differ for a variety of reasons, including prior exposure to smallpox and previous vaccination. The level of prior vaccination and naturally acquired immunity differed from town to town. In Leicester, for example, only 50%-60% of the population had been vaccinated at the time of the outbreak (1892) (9). Thus, in considering attack rates as a measure of rate of transmission, it is important to define both the population of susceptible persons and their degree of contact with an infectious person (e.g., whether they live in the same house as an infectious person). Clearly, not all susceptible persons are at equal risk. This requirement makes it very difficult to use existing data regarding attack rates to calculate an average rate of transmission.

Given the problems associated with the first two methods of calculating a transmission rate, we must therefore rely on data that directly measure the number of persons infected per infectious person. In almost any situation, there is likely to be a wide range in the numbers infected per infectious person (Tables 4,5; Figure). The reason for such variability is that, despite the fact that smallpox can be transmitted by aerosolized particles (1), it is not as easily transmissible as, for example, measles (Table 1). Some form of sustained face-to-face contact is needed to ensure transmission (Table 5). If such close contact is a typical (but not necessarily sole) requirement for transmission, then the data in Tables 2 and 3 can be readily explained.

Despite strong evidence that one person can infect many others, available data suggest that the average rate of transmission is <2 persons infected per infectious person (Table 4; Figure). Given the large percentage of the population in the United States that is now susceptible (i.e., never exposed to or vaccinated against smallpox), the average transmission rate following a deliberate release of smallpox might be >2. Unfortunately, the probability that the average transmission rate will be >2 cannot be demonstrated reliably. Thus, in our model, we examine the impact of three rates of transmission: 2, 3, and 5 persons infected per infectious. Our data suggest that the lowest rate (2 persons infected per infectious person) is the most accurate representation of previous transmission rates.
References

1. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization; 1988.
2. Rao AR. Smallpox. Bombay: The Kothari Book Depot, 1972.
3. Dixon CW. Smallpox. London: Churchill; 1962.
4. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. New York: Oxford University Press; 1991.
5. Henderson DA. Smallpox eradication. Proc R Soc Lond B Biol Sci 1977;68:83-97.
6. Arita I, Wickett J, Fenner F. Impact of population density on immunization programmes. J Hyg Camb 1986;96:459-66.
7. Basu RN, Jezek Z, Ward NA. The eradication of smallpox from India. New Delhi: World Health Organization, South-east Asia Regional Office; 1979.
8. Foege WH, Millar JD, Lane JM. Selective epidemiologic control in smallpox eradication. Am J Epidemiol 1971;94:311-5.
9. Royal Commission on Vaccination. A report on vaccination and its results, based on evidence taken by the Royal Commission during the years 1889-1897. Vol 1. The text of the commission report. London: New Sydenham Society; 1898.
10. Thomas DB, Arita I, McCormack WM, Khan MM, Islam S, Mack TM. Endemic smallpox in rural East Pakistan. II. Intravillage transmission and infectiousness. Geneva: World Health Organization (WHO/SE/71.25); 1971.
11. Thomas DB, McCormack WM, Arita I, Khan M, Islam S, Mack TM. Endemic smallpox in a rural area. Geneva: World Health Organization (WHO/SE/69.11); 1969.
12. Thomas DB, McCormack WM, Arita I, Khan MM, Islam S, Mack TM. Endemic smallpox in rural east Pakistan: I. Methodology, clinical and epidemiological characteristics of cases, and intervillage transmission. Geneva: World Health Organization (WHO/SE/71.24); 1971.
13. Arnt N, Morris L. Epidemiological characteristics of smallpox outbreaks in two small Brazilian villages. Geneva: World Health Organization (WHO/SE/70.22); 1970.
14. Pifer J, Adeoye CL. Characteristics of an epidemic of smallpox: Gerere hamlet, Nigeria, 1968. Geneva: World Health Organization (WHO/SE/68.5); 1968.
15. Rao AR, Paramasivam TV, Kamalakshi S, Parasuraman AR, Shantha M. A short report of epidemiological investigations of smallpox outbreaks in 1969 in a few villages of Nellore district of Andrapradesh, India. Geneva; World Health Organization (WHO/SE/70.17); 1970.
16. Rao AR. An outbreak of smallpox in Chingleput district, Madras. Geneva: World Health Organization (WHO/SE/68.6); 1968.
17. Rangaraj AG. An outbreak of smallpox in a village in Afghanistan. Geneva: World Health Organization (WHO/SE/69.9); 1969.
18. Heiner GG, Fatima N, McGrumb FR. A study of intrafamilial transmission of smallpox. Am J Epidemiol, 1971;94:316-326.
19. de Quadros CCA, Morris L, da Costa EA, Arnt N, Tigre CH. Epidemiology of variola minor in Brazil: A study of 33 outbreaks. Geneva: World Health Organization (WHO/SE/71.32); 1971.
20. de Costa EA, Morris L. Smallpox epidemic in a Brazilian community. Geneva: World Health Organization (WHO/SE/74.64); 1974.
21. Rao AR. A short report on the epidemiological findings of smallpox outbreaks in the state of Tamil Nadu, July 1968--June 1969. Geneva: World Health Organization (WHO/SE/70.19); 1970.
22. Singh S. Some aspects of the epidemiology of smallpox in Nepal. Geneva: World Health Organization (WHO/SE/69.10); 1969.
23. Rao AR. A short report on epidemiological findings of smallpox outbreaks in the city of Madras. Geneva: World Health Organization (WHO/SE/68.7); 1968.
24. de Sario V. Field investigation of an outbreak of smallpox at Bawku, Ghana: May-October, 1967. Geneva: World Health Organization (WHO/SE/69.24); 1969.
25. Suleimanov GD, Mandokhel KK. Smallpox transmission on a bus. Geneva: World Health Organization (WHO/SE/72.41); 1972.
26. Presthus GT, Sibiya JB. A persistent focus of smallpox in Botswana. Geneva: World Health Organization (WHO/SE/74.89); 1974.
27. Litvinjenko S, Arsic B, Borjanovic S. Epidemiologic aspects of smallpox in Yugoslavia in 1972. Geneva: World Health Organization (WHO/SE/73.57); 1973.
28. Wehrle PF, Posch J, Richter KH, Henderson DA. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull World Health Organ 1970;43:669-79.
29. Great Britain Ministry of Health. Smallpox, 1961-62. Reports on public health and medical subjects, No. 109. London: Her Majesty's Stationery Office; 1963.
30. Henderson DA, Yekpe M. Smallpox transmission in southern Dahomey: a study of a village outbreak. Am J Epidemiol 1969;90:423-8.
31. Smallpox Eradication Unit (WHO, Geneva). A smallpox outbreak in Merka town, Somalia. Geneva: World Health Organization (WHO/SE/78.123); 1978.
32. Anderson RM, May RM. Vaccination against rubella and measles: quantitative investigations of different policies. J Hyg Camb 1983;90:259-325.
33. Cliff AD, Haggett P. Statistical modeling of measles and influenza outbreaks. Stat Methods Med Res 1993;2:43-73.
34. Henderson DA. Principles and lessons from the smallpox eradication programme. Bull World Health Organ 1987;65:535-46.

1. The data in Table 2 indicate some age-specific risk, both among the vaccinated and unvaccinated. However, the risk does not appear to have a consistent pattern. For example, among those with a history of vaccination living in a house with a smallpox patient, those >10 years of age had a higher attack rate than those <10 years of age. Yet, among the unvaccinated, those <10 years of age had a higher attack rate than those >10 years of age. This relationship between vaccination status, age, and attack rate is repeated in the general population.

**Selected Sources**

- Anderson RM. Transmission dynamics and control of infectious disease agents. In: Anderson RM, May RM, editors. Population biology of infectious diseases. Berlin: Springer-Verlag; 1982. p. 149-77.
• Anderson RM, May RM. Population biology of infectious diseases: Part I. Nature 1979;280:361-7.
• Anderson RM, May RM. Population biology of infectious diseases: Part II. Nature 1979;280:455-61.
• Anderson RM, May RM. Directly transmitted infectious diseases: control by vaccination. Science 1982;215:1053-60.
• Aron JL, May RM. The population dynamics of malaria. In: Anderson RM, editor. The population dynamics of infectious diseases: theory and application. London: Chapman and Hall; 1982.
• Bartlett MS. Measles periodicity and community size. J Royal Stat Soc Series A 1957;120:48-60.
• Bardi J. Aftermath of a hypothetical smallpox disaster. Emerg Infect Dis 1999;5:547-51.
• Bartlett MS. Critical community size for measles in the United States. J Royal Stat Soc Series A 1960;123:37-44.
• Christie AR. Infectious diseases: epidemiology and clinical practice. 3rd ed. New York: Churchill Livingstone; 1980.
• Cliff AD, Haggett P. Statistical modeling of measles and influenza outbreaks. Stat Methods Med Res 1993;2:43-73.
• Deria A, Jezek Z, Foster S. Outbreak containment in the Somalia smallpox eradication programme. Geneva: World Health Organization (WHO/SE/78.104); 1978.
• Frauenthal JC. Smallpox: When should routine vaccination be discontinued? The UMAP Expository Monograph Series. Boston: Birkhäuser; 1981.
• Glokpor GF, Agle AN. Epidemiological investigations--Smallpox Eradication Programme in Togo: 1969. Geneva: World Health Organization (WHO/SE/70.21); 1970.
• Henderson DA. Smallpox: Clinical and epidemiological features. Emerg Infect Dis 1999;5:537-9.
• Henderson DA. The looming threat of bioterrorism. Science 1999;283:1279-82.
• Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling EP, et al. Smallpox as a biological weapon: Medical and public health management. JAMA 1999;281:2127-37.
• Kaufmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack: Are prevention and postattack intervention programs justifiable? Emerg Infect Dis 1997;3:83-94.
• Mack TM. Smallpox in Europe, 1950-1971. J Infect Dis 1972;125:161-9.
• O'Toole T. Smallpox: An attack scenario. Emerg Infect Dis 1999;5:540-6.
• Pattanayak S, Sehgal PN, Raghavan NGS. Outbreaks of smallpox during 1968 in some villages of Jaipur district, Rajasthan. Geneva: World Health Organization (WHO/SE/70.20); 1970.
• Smith ADM. Epidemiological patterns in directly transmitted human infections. In: Croll NA, Cross JH, editors. Human ecology and infectious diseases. New York: Academic Press; 1983. p. 333-51.
• Statistical abstracts of the United States: 1999. 119th ed. Washington: U.S. Bureau of the Census; 1999.
Modeling Potential Responses to Smallpox as a Bioterrorist Weapon

Martin I. Meltzer,* Inger Damon,* James W. LeDuc,* and J. Donald Millar†

*Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Don Millar & Associates, Inc., Atlanta, Georgia, USA

Appendix II: Modeling Potential Responses to Smallpox as a Bioterrorist Weapon: Additional Results from Sensitivity Analyses

Table 1. Sensitivity analyses: Effect on number of cases of smallpox as a result of variations in numbers initially infected, numbers infected per infectious person, intervention start days, and quarantine and vaccination effectiveness.

| No. initially infected | No. infected per infectious person | Start day | Quarantine: % removal per day | Vaccination: % reduction in transmission | Cumulative total cases at 365 days | Daily cases at 365 days | Increase or decrease (+/−) |
|------------------------|-----------------------------------|-----------|-------------------------------|------------------------------------------|-------------------------------|------------------------|--------------------------|
| 100                    | 2                                 | 30        | 10                            | Nil                                      | 1.5 million                  | 32,548                 | +                        |
| 100                    | 2                                 | 30        | 10                            | Nil                                      | 2,455                        | 2                      | −                        |
| 100                    | 2                                 | 45        | 10                            | Nil                                      | 10,512                       | 51                     | +                        |
| 100                    | 2                                 | 45        | 25                            | 33                                       | 6,063                        | 8                      | −                        |
| 100                    | 2                                 | 45        | 25                            | Nil                                      | 1,548                        | 0                      | −                        |
| 100                    | 5                                 | 30        | 25                            | Nil                                      | 4,879                        | 4                      | −                        |
| 100                    | 5                                 | 30        | 25                            | Nil                                      | 54.5 million                 | 1.6 million             | +                        |
| 100                    | 5                                 | 30        | 50                            | Nil                                      | 9.4 million                  | 220,562                 | +                        |
| 100                    | 5                                 | 30        | 70                            | Nil                                      | 24,437                       | 75                     | +                        |
| 100                    | 5                                 | 30        | 80                            | Nil                                      | 6,282                        | 1                      | −                        |
| 100                    | 5                                 | 45        | 70                            | Nil                                      | 19,821                       | 1                      | −                        |
| 1,000                  | 2                                 | 30        | 10                            | Nil                                      | 14.8 million                 | 325,480                 | +                        |
| 1,000                  | 2                                 | 30        | 25                            | 25                                       | 105,117                      | 511                    | +                        |
| 1,000                  | 2                                 | 30        | 33                            | 33                                       | 30,872                       | 37                     | −                        |
| 1,000                  | 2                                 | 45        | 25                            | Nil                                      | 48,975                       | 37                     | −                        |
| 1,000                  | 2                                 | 45        | 10                            | 33                                       | 60,392                       | 78                     | −                        |
| 1,000                  | 2                                 | 45        | 25                            | 33                                       | 15,471                       | 0                      | −                        |

*aNumber initially infected refers to those who are exposed during a release such that they become infectious. This excludes those who are exposed but either do not become ill or do not become infectious.

*bThe number of persons infected per infectious person is the transmission rate.

*cStart day, for both quarantine and vaccination interventions, refers to the day postrelease, with the day of release being day 1.

*dQuarantine refers to removal of infectious persons only, starting on the first day of overt symptoms (i.e., rash).
At a 25% daily removal rate, a cohort of all those entering the first day of overt symptoms is entirely removed in 17 days (18 to 20 days post incubation) after day 1 of overt symptoms, with 90% removed in 9 days. At a 10% daily removal, a cohort of all those entering the first day of overt symptoms is entirely removed in 44 days (45 to 47 days post incubation) after day 1 of overt symptoms, with 90% removed in 22 days. At a daily removal rate of 80%, a cohort of all those entering their first day of overt symptoms is entirely removed in 3 days (4 to 6 days post incubation) after day 1 of overt symptoms, with 90% removed in 2 days.

Vaccination is assumed to reduce the transmission rate by a given percentage (e.g., 25% reduction results in transmission declining from 2.0 to 1.5 persons infected per infectious person, and 33% reduces transmission from 2.0 to 1.32).

\(\text{(+)}\) = an increasing rate of daily cases on day 365, and thus the modeled interventions will not stop the transmission of smallpox. \((-)\) = a decreasing rate of daily cases, such that the interventions modeled will eventually stop the transmission of smallpox.

\(\text{Nil} = \) vaccine not used in this scenario.

**Table 2.** Sensitivity analyses: minimum levels of intervention needed to stop transmission of smallpox by days 75, 150, and 225 postrelease

| Target stop day\(^a\) | Start day of interventions\(^a\) | No. infected per infectious person\(^b\) | Quarantine: Minimum % removal per day\(^c\) | Vaccination: Minimum % reduction in transmission (transmission rate)\(^d\) |
|-----------------------|---------------------------------|----------------------------------------|------------------------------------------|------------------------------------------|
| 75                    | 30                              | 3                                      | 99.4                                     | Nil\(^e\) (3.00)                         |
| 75                    | 30                              | 3                                      | Nil\(^f\)                                | 90.5 (0.29)                              |
| 75                    | 30                              | 3                                      | 25                                       | 76.7 (0.70)                              |
| 75                    | 30                              | 3                                      | 50                                       | 56.2 (1.32)                              |
| 75                    | 30                              | 3                                      | 82.5                                     | 25.0 (2.25)                              |
| 75                    | 30                              | 2                                      | 25                                       | 58.0 (0.84)                              |
| 75                    | 30                              | 5                                      | 50                                       | 78.9 (1.06)                              |
| 75                    | 45                              | 2                                      | 50                                       | 58.5 (0.83)                              |
| 75                    | 45                              | 3                                      | 50                                       | 81.2 (0.57)                              |
| 150                   | 30                              | 3                                      | 63.5                                     | Nil\(^e\) (3.00)                         |
| 150                   | 30                              | 3                                      | Nil\(^f\)                                | 80.0 (0.60)                              |
| 150                   | 30                              | 3                                      | 25                                       | 53.7 (1.39)                              |
| 150                   | 30                              | 3                                      | 50                                       | 19.7 (2.41)                              |
| 150                   | 30                              | 3                                      | 46.2                                     | 25.0 (2.25)                              |
| 150                   | 30                              | 2                                      | 25                                       | 25.8 (1.49)                              |
| 150                   | 30                              | 5                                      | 50                                       | 55.7 (2.22)                              |
| 150                   | 45                              | 2                                      | 50                                       | Nil\(^f\) (2.00)                         |
| 150                   | 45                              | 3                                      | 50                                       | 33.3 (2.00)                              |
| 225                   | 30                              | 3                                      | 53.8                                     | Nil\(^e\) (3.00)                         |
| 225                   | 30                              | 3                                      | Nil\(^f\)                                | 75.8 (0.73)                              |
| 225                   | 30                              | 3                                      | 25                                       | 45.2 (1.65)                              |
| 225                   | 30                              | 3                                      | 50                                       | 6.0 (2.82)                               |
| 225                   | 30                              | 3                                      | 38.1                                     | 25.0 (2.25)                              |
| 225                   | 30                              | 2                                      | 25                                       | 14.3 (1.72)                              |
| 225                   | 30                              | 5                                      | 50                                       | 46.5 (2.68)                              |
| 225                   | 45                              | 2                                      | 50                                       | Nil\(^f\) (2.00)                         |
| 225                   | 45                              | 3                                      | 50                                       | 14.8 (2.56)                              |

\(^a\)Target stop day and start day of interventions refer to days postrelease, with day of release being day 1.

\(^b\)The number of persons infected per infectious person is the transmission rate.

\(^c\)Quarantine refers to removal of infectious persons only, starting on the first day of overt symptoms (i.e., rash). Rates are the minimum rates needed, when combined with vaccination, to ensure that there is zero transmission.
by the target date. With 25% daily removal rate of infectious persons, a cohort of all those entering the first day of overt symptoms is entirely removed in 17 days (18 to 20 days postincubation) after day 1 of overt symptoms, with 90% removed in 9 days after entering overtly symptomatic period. With 50% daily removal of infectious persons, a cohort of all those entering their first day of overt symptoms is entirely removed in 7 days (8 to 10 days postincubation) after day 1 of overt symptoms, with 90% removed in 4 days after entering overtly symptomatic period.

*Vaccination assumed to reduce the transmission rate by a given percentage (e.g., 25% reduction results in transmission decreasing from 3.0 to 2.25 persons infected per infectious person). Percentages are the minimum percentage reduction in the assumed rate of transmission needed, when combined with quarantine, to ensure zero transmission by the target date. The resultant transmission rate, after reduction, is in parentheses.*

*For these scenarios, the assumed quarantine rate is such that the target dates can be attained without the use of vaccination.*

*For these scenarios, the assumed vaccination-induced reduction in transmission is such that the target dates can be attained without the use of quarantine.*